“Novartis Researchers Characterize Novel Ligands for Tissue-Selective E3 Ligase TRIM58 with Potential for Targeted Protein Degradation”

https://pubmed.ncbi.nlm.nih.gov/38116426

Researchers from Novartis have discovered and characterized novel ligands for TRIM58, a tissue-selective E3 ligase expressed in erythroid precursor cells, with potential for targeted protein degradation.